Filing Summary
Company and period: Alterity Therapeutics Limited, a development-stage enterprise, filed this Form 6-K as a foreign private issuer for October 2026. The report was signed on October 5, 2026.
Business context: The filing lists Exhibit 99.1, “Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA.” The supplied filing text does not include the exhibit’s analysis or study results.
Financial and Operating Information
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also provides no clear comparison with a prior period, guidance, or financial outlook.
Other Filing Details
The 6-K states that it is incorporated by reference into the company’s specified Form S-8 and Form F-3 registration statements. The company indicates it files annual reports on Form 20-F.
Key Facts to Verify
- Review Exhibit 99.1 for the actual ATH434 Phase 2 analyses, data, and any stated limitations.
- Check subsequent filings for additional trial updates, financial results, or outlook.
- Confirm the implications of incorporating this 6-K into the identified registration statements.